Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

Phase II results for cemiplimab in Pts with laBCC Alexander Stratigos, M.D.Подробнее

Alexander Stratigos, MD, PhD, speculates on next steps in the development of cemiplimab in BCCПодробнее

How Prevalent is Advanced CSCC?Подробнее

Real-World Management of Patients on CemiplimabПодробнее

Cemiplimab in Managing Advanced cSCCПодробнее

Dr. Pavlick on Longer Follow-Up Data With Cemiplimab in CSCCПодробнее

Alexander Stratigos, MD, PhD, on the latest data investigating the use of cemiplimab in BCCПодробнее

Cemiplimab in advanced BCCПодробнее

Second-Line Systemic Treatment of BCCПодробнее

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinomaПодробнее

The miR Scientific Sentinel AssayПодробнее

Vismodegib in basal cell carcinomaПодробнее

Cemiplimab plus ipilimumab for advanced NSCLCПодробнее

Findings for Cemiplimab in Advanced or Recurrent Cervical CancerПодробнее

Advanced/Metastatic cSCC Treatment OptionsПодробнее

Real-life data with sonidegib for locally advanced basal cell carcinomaПодробнее

Advances and Challenges in the Management of Basal Cell Carcinoma - Dr. Aleksander SekulicПодробнее

SURPASS: evaluating the next-generation of SPEAR T-cell therapyПодробнее